Neurogenic Detrusor Overactivity Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Neurogenic Detrusor Overactivity Market Size Forecast: How Large Could The Market Become By 2030?
The market for neurogenic detrusor overactivity has experienced robust growth in recent years. Its value is projected to rise from $1.82 billion in 2025 to $1.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. Historical expansion has been driven by factors such as the scarcity of effective NDO treatments, dependence on traditional surgical approaches, a higher incidence of neurogenic bladder conditions, improved hospital and urology clinic facilities, and insufficient awareness among patients and caregivers.
Between now and 2030, the neurogenic detrusor overactivity market is projected to experience robust growth, reaching a value of $2.63 billion at a compound annual growth rate of 7.6%. This forecasted expansion is driven by several key factors, including the development of new pharmacological treatments, progress in minimally invasive surgical techniques, the integration of neuromodulation devices, the growing use of continuous patient monitoring technologies, and increased funding for long-term care and rehabilitation services. Major trends shaping this period comprise the rising preference for antimuscarinic and beta-3 adrenergic agonists, the greater application of neuromodulation and less invasive treatments, the broadening of behavioral therapy and patient education initiatives, heightened attention to urodynamic and ultrasound monitoring, and a rising awareness of quality-of-life evaluations and chronic care requirements.
Download A Free Sample Report For Comprehensive Market Insights:
Neurogenic Detrusor Overactivity Market Demand Drivers: What Is Fueling Industry Growth?
The growth of the neurogenic detrusor overactivity market is expected to be driven by the increasing prevalence of neurological disorders. These disorders, which impair movement, sensation, cognition, or other bodily functions, result from damage to the brain, spinal cord, or nerves. As life expectancy rises, age-related brain degeneration becomes more common, fueling the increase in neurological conditions. A frequent bladder complication linked to such disorders—including spinal cord injury, multiple sclerosis, and Parkinson’s disease—is neurogenic detrusor overactivity (NDO), where disrupted nerve signaling between the brain and bladder causes involuntary contractions. According to a study published in April 2024 by the American Academy of Neurology (AAN), an organization based in the US, global brain disorder cases are projected to reach 4.9 billion by 2050—a 22 percent rise from the approximately 4 billion recorded in 2021. Consequently, the rising number of neurological disorders is accelerating expansion in the NDO market.
Neurogenic Detrusor Overactivity Market Segment Analysis: What Are The Major Market Categories?
The neurogenic detrusor overactivity market covered in this report is segmented –
1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
2) By Application: Adult, Child
3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
Neurogenic Detrusor Overactivity Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the market for treating neurogenic detrusor overactivity (NDO) are concentrating on creating cutting-edge generic therapies, like beta-3 adrenergic receptor agonists, to provide cost-effective bladder control treatments. These agonists, including mirabegron, work by relaxing the bladder’s detrusor muscle, which boosts bladder capacity and lessens issues such as urgency and incontinence. As an example, in April 2024, Lupin Ltd., a pharmaceutical firm based in India, gained clearance from the U.S. Food and Drug Administration (USFDA) to bring Mirabegron, the generic counterpart of Myrbetriq, to the American market. This once-daily oral medication offers a convenient and efficacious choice for individuals dealing with overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), particularly in pediatric cases. The approval highlights Lupin’s dedication to enhancing the availability of superior, reasonably priced generic drugs across vital therapeutic fields.
Neurogenic Detrusor Overactivity Market Leading Companies Driving Competitive Growth
Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.
Access The Complete Neurogenic Detrusor Overactivity Market Report:
Neurogenic Detrusor Overactivity Market Geographic Distribution And Regional Opportunities
North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
